Protective effect of Melatonin, Rosuvastatin and their combination against Amikacin induced nephrotoxicity in rats

Abstract

The current work was conducted to study the possible protective effect of melatonin, rosuvastatin and combination of them on nephrotoxicityinduced by amikacin in rats. Forty adult male albino rats were allocated into five groups (8 animalseach) and were treated daily for 2 weeks as follows: Group I::(control group) treated with dimethylsulfoxide (DMSO) orally.GroupII: injected with daily dose of (120 mg/kg/IP) of amikacin;Group III: injected with daily doseamikacin (120 mg/kg) with daily oral dose of melatonin (10 mg/kg); Group IV: injected with daily dose amikacin (120 mg/kg)with daily oral dose ofrosuvastatin (10 mg/kg);GroupV:animals were injected with daily dose amikacin (120 mg/kg) simultaneously treated with a combination of melatonin and rosuvastatin with the previously mentioned doses respectively. After 2 weeksblood samples were obtained for biochemical analyses. Then, rats were sacrificed and the kidneyswere collected for tissue homogenization and histopathological study. Results: amikacin administration induced significant increase in kidney weight, serumurea and creatinine, tumor necrosis factor (TNF-α), tissue malondialdehyde (MDA) levels and reduction in superoxide dismutase(SOD) activity. Simultaneous administration of melatonin and rosuvastatin treatment with amikacin significantly lowered the elevated serum urea and creatinine concentration, kidney weight, serum TNF-α and renal MDA andsignificantly enhance renal SOD activity with improvement of the kidney histological findings in comparison with group II. Conclusion: it could be concluded that combination of melatonin and rosuvastatin may be useful for reducing the nephrotoxic effects of amikacin.